Alert: Psilocybin FDA Approval Prospects Strengthened by Compass Phase 3 Data

Experts are interpreting Compass Pathways' recent Phase 3 psilocybin data for treatment-resistant depression as a strong indicator that FDA approval is now a matter of 'when, not if.' This development, if realized, would mark a significant federal milestone for psilocybin, potentially influencing future regulatory frameworks and market access for psychedelic compounds.